CS
BLUE

Cannell & Spears’s bluebird bio BLUE Stock Holding History

Cannell & Spears’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-361
Closed -$202K – 230
2020
Q4 		$202K Sell
361
-3
-0.8% -$1.9K 0.02% 225
2020
Q3 		$254K Hold
364
– – 0.02% 184
2020
Q2 		$288K Buy
+364
New +$274K 0.03% 166

Other funds holding BLUE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Cannell & Spears's BLUE Position: Q1 2021 in Review

Cannell & Spears sold out of bluebird bio (BLUE) in Q1 2021, closing a stake of 361 shares — an estimated $202K sold.

Cannell & Spears first reported a position in BLUE in Q2 2020 and held it in 3 quarters. The position peaked at $288K in Q2 2020. 229 funds tracked by Wall St. Rank hold BLUE as of Q1 2021.

  • Cannell & Spears reported no remaining bluebird bio position as of Q1 2021 after selling out during the quarter.
  • Cannell & Spears sold 361 bluebird bio shares in Q1 2021, an estimated $202K.
  • Cannell & Spears first reported a position in bluebird bio in Q2 2020 and held it in 3 quarters.
  • Cannell & Spears's bluebird bio position peaked at $288K in Q2 2020.
  • 229 funds tracked by Wall St. Rank held bluebird bio as of Q1 2021.

Based on Cannell & Spears's 13F filing for Q1 2021, filed 14 May 2021.